Individualized risk stratification for postmastectomy radiation therapy in node-positive breast cancer: moving beyond universal guidelines.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: ≥4 positive lymph nodes
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Clinical decision-making must consider treatment benefits relative to potential late toxicities and reconstructive complications. Personalized, evidence-based approaches informed by emerging trial data represent the optimal strategy for patient management.
Postmastectomy radiation Therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality in patients with ≥4 positive lymph nodes.
- 연구 설계 meta-analysis
APA
Yamada A, Narui K, et al. (2026). Individualized risk stratification for postmastectomy radiation therapy in node-positive breast cancer: moving beyond universal guidelines.. Japanese journal of clinical oncology, 56(1), 5-11. https://doi.org/10.1093/jjco/hyaf153
MLA
Yamada A, et al.. "Individualized risk stratification for postmastectomy radiation therapy in node-positive breast cancer: moving beyond universal guidelines.." Japanese journal of clinical oncology, vol. 56, no. 1, 2026, pp. 5-11.
PMID
41066690
Abstract
Postmastectomy radiation Therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality in patients with ≥4 positive lymph nodes. However, evidence supporting PMRT in patients with 1-3 positive nodes remains limited. While the 2014 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated benefit in this population, the constituent trials preceded current standard practices including sentinel lymph node biopsy, contemporary systemic therapies, and modern radiation therapy techniques. This analysis examines the applicability of EBCTCG findings to current clinical practice. Historical trials reported elevated LRR rates, potentially attributable to inadequate axillary staging and suboptimal systemic therapy regimens such as cyclophosphamide, methotrexate, and fluorouracil. Contemporary studies demonstrate substantially lower LRR rates in comparable patients managed without PMRT, particularly those with favorable tumor characteristics. Current adjuvant therapies-including anthracyclines, taxanes, trastuzumab, endocrine agents, and targeted therapies such as abemaciclib and olaparib-have markedly reduced recurrence risk. Retrospective analyses yield conflicting results regarding PMRT efficacy, while randomized trials (SUPREMO, TAILOR RT) seek to refine treatment indications. Contemporary practice should not universally recommend PMRT for intermediate-risk patients (1-3 nodes); instead, individualized risk assessment is warranted. The role of PMRT remains undefined in patients without axillary lymph node dissection or those achieving pathologic complete response following neoadjuvant therapy. Clinical decision-making must consider treatment benefits relative to potential late toxicities and reconstructive complications. Personalized, evidence-based approaches informed by emerging trial data represent the optimal strategy for patient management.
MeSH Terms
Humans; Breast Neoplasms; Female; Mastectomy; Risk Assessment; Practice Guidelines as Topic; Lymphatic Metastasis; Radiotherapy, Adjuvant; Neoplasm Recurrence, Local
같은 제1저자의 인용 많은 논문 (5)
- Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insurance.
- Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
- Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma.
- Use of Handheld Ultrasound for Flap Monitoring after Free Jejunal Transfer.
- Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers.